Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

Eli Lilly HQ

Lilly says insulin peglispro too risky to pursue

Discontinues development of medicine once tipped as a diabetes blockbuster

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

Merck seeks oasis in CETP inhibitor desert

Pledgesto continue anacetrapib trials despite series of failures in its class

- PMLiVE

J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m

- PMLiVE

Merck defeated in antibiotic patent case in US

Loses four patents protecting Cubicin from generic competition

- PMLiVE

At long last, Merck gets FDA panel backing for Bridion

Unanimous vote in favour of drug suggest it is back on course for approval

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

Sanofi reception

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi reception

Sanofi and Hanmi collaborate on diabetes treatments

Aims to optimise efficacy of medications

- PMLiVE

Merck and MacroGenics collaborate on immuno-oncology

Evaluates margetuximab with Keytruda for gastric cancer

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links